Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 300
Filter
4.
FP Essent ; 541: 14-19, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38896826

ABSTRACT

Bacterial skin infections represent a significant health care burden. Cellulitis and erysipelas are rapidly spreading, painful, superficial skin infections, usually caused by streptococci or Staphylococcus aureus. Folliculitis is an infection of hair follicles mostly caused by S aureus. Simple folliculitis typically is self-limited. Topical benzoyl peroxide is a first-line nonantibiotic treatment. Mupirocin and clindamycin are topical antibiotic options. For treatment-resistant cases, oral cephalexin or dicloxacillin is an appropriate option. Impetigo is a common, self-limited infection in children. Bullous impetigo is caused by S aureus, and nonbullous impetigo is caused by beta-hemolytic streptococci, S aureus, or both. In most cases, topical mupirocin or retapamulin (Altabax) is effective. Oral antibiotics should be considered for household outbreaks or patients with multiple lesions. Abscesses are red, painful collections of purulence in the dermis and deeper tissues caused by S aureus or polymicrobial infections. Furuncles are abscesses of a hair follicle, whereas carbuncles involve several hair follicles. In recurrent cases of these lesions, culture of the exudate is recommended. Abscess, furuncle, and carbuncle management consists of incision and drainage. Oral antibiotics are not necessary in most cases but should be prescribed for patients with severe immunocompromise or systemic signs of infection. In bacterial skin infections, methicillin-resistant S aureus coverage should be considered for patients with infections that have not improved with treatment.


Subject(s)
Anti-Bacterial Agents , Cellulitis , Impetigo , Skin Diseases, Bacterial , Humans , Child , Anti-Bacterial Agents/therapeutic use , Adolescent , Impetigo/diagnosis , Impetigo/drug therapy , Skin Diseases, Bacterial/diagnosis , Skin Diseases, Bacterial/drug therapy , Skin Diseases, Bacterial/microbiology , Skin Diseases, Bacterial/therapy , Cellulitis/diagnosis , Cellulitis/drug therapy , Cellulitis/microbiology , Cellulitis/therapy , Folliculitis/diagnosis , Folliculitis/drug therapy , Folliculitis/microbiology , Erysipelas/diagnosis , Erysipelas/drug therapy , Abscess/diagnosis , Abscess/therapy , Abscess/microbiology , Furunculosis/diagnosis , Furunculosis/drug therapy , Furunculosis/therapy , Furunculosis/microbiology , Carbuncle/diagnosis , Carbuncle/therapy
6.
J Int Med Res ; 51(12): 3000605231217950, 2023 Dec.
Article in English | MEDLINE | ID: mdl-38102997

ABSTRACT

Impetigo herpetiformis is a rare skin disease that most often occurs in the third trimester of pregnancy. It is currently considered as a form of generalized pustular psoriasis and the typical skin lesions comprise small sterile pustules. Here, a case of impetigo herpetiformis in the second trimester of pregnancy after 7 weeks of hydroxychloroquine administration for suspected Sjogren's syndrome is reported. Treatment with anti-infective, anti-inflammatory and immunosuppressive medication did not improve the patient's condition. Following delivery of a live male by emergency caesarean section at 29 weeks' gestation, the rash was reported to be completely resolved by 3 months postpartum. Previously published cases of impetigo herpetiformis in the second trimester of pregnancy that were retrieved from a search of the PubMed database are also reviewed and discussed.


Subject(s)
Dermatitis Herpetiformis , Exanthema , Impetigo , Pregnancy Complications, Infectious , Psoriasis , Female , Humans , Pregnancy , Cesarean Section , Dermatitis Herpetiformis/diagnosis , Dermatitis Herpetiformis/drug therapy , Dermatitis Herpetiformis/pathology , Impetigo/diagnosis , Impetigo/drug therapy , Pregnancy Trimester, Second , Psoriasis/pathology
7.
J Paediatr Child Health ; 59(12): 1296-1303, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37920140

ABSTRACT

AIM: Here, we present results of a survey of scabies prevalence in childcare centres and primary schools in Auckland. METHODS: Children whose parents agreed to take part in participating centres in the Auckland region were examined for scabies by general practitioners and given questionnaires of relevant symptoms. Diagnoses of clinical or suspected scabies were made according to the International Alliance for the Control of Scabies (IACS) criteria. The survey was a stratified random sample of schools and early childcare centres. A quantitative polymerase chain reaction (PCR) test was also used to complement the IACS criteria. RESULTS: A total of 181 children were examined, with 145 children with history information, 16 of whom (11.0%) met the criteria for 'clinical' or 'suspected' scabies. Weighted analysis, accounting for the survey design, indicated that the prevalence of scabies in early childcare centres was 13.2% (95% CI: 4.3 to 22.1), with no school-aged children fulfilling these criteria. A higher proportion had clinical signs of scabies with 23 (12.7%) having typical scabies lesions and a further 43 (23.8%) had atypical lesions. A total of 64 PCR tests were taken and 15 (23%) were positive. None of these cases were receiving treatment for scabies. Five were undergoing topical skin treatment: three with topical steroid and two with calamine lotion. CONCLUSIONS: The prevalence of children with scabies is high in early childcare centres in Auckland. Misdiagnosis is suggested by several PCR positive cases being treated by topical agents used to treat other skin conditions.


Subject(s)
Impetigo , Scabies , Child , Humans , Scabies/diagnosis , Scabies/epidemiology , Impetigo/diagnosis , Impetigo/drug therapy , Impetigo/epidemiology , Prevalence , Schools , Surveys and Questionnaires , Diagnostic Errors
8.
Eur Rev Med Pharmacol Sci ; 27(19): 9273-9278, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37843341

ABSTRACT

OBJECTIVE: Ozenoxacin is a new antibiotic used to treat non-bullous impetigo. The aim of this study is to evaluate the microbiological and clinical efficacy of topical ozenoxacin 1% cream after 5-day twice-daily treatment, in pediatric patients with impetigo. PATIENTS AND METHODS: This observational and prospective study included patients aged 6 months to 18 years, with non-bullous impetigo. Efficacy was measured using the Skin Infection Rating Scale (SIRS) and microbiological culture at the first visit (T0), at the second visit after 72 hours (T1) and after 5 days (T2). Safety and tolerability were also evaluated. RESULTS: A total of 50 patients was enrolled. A reduction of SIRS score >10% after 72 hours of treatment was noticed in all patients, while a complete reduction was assessed after 5 days in all the population. Microbiologic success rates for ozenoxacin at T1 was 92% (four patients had original pathogens in the specimen culture from the skin area), whereas at T2, it was 100%. CONCLUSIONS: Topical ozenoxacin has strong efficacy in treating impetigo in pediatric patients. Ozenoxacin's clinical and microbiological rapid onset of response led to consider this antibiotic a novel efficacy option for the treatment of impetigo.


Subject(s)
Impetigo , Humans , Child , Impetigo/diagnosis , Impetigo/drug therapy , Impetigo/microbiology , Prospective Studies , Anti-Bacterial Agents , Systemic Inflammatory Response Syndrome
9.
Mil Med ; 188(5-6): e1332-e1334, 2023 05 16.
Article in English | MEDLINE | ID: mdl-37191635

ABSTRACT

The differential diagnosis of vesiculobullous lesions can be intimidating to the primary care provider. While some entities such as bullous impetigo may easily be diagnosed clinically if the patient's demographics as well as the lesion morphology and distribution present classically, atypical presentations may require additional laboratory studies for confirmation. We describe a case of bullous impetigo with characteristics that clinically mimicked two rare immunobullous dermatoses. Although extensive diagnostic testing was performed, we recommend an approach for primary care providers to initiate empiric treatment while maintaining awareness of less common immunobullous entities.


Subject(s)
Impetigo , Skin Diseases, Vesiculobullous , Soft Tissue Injuries , Humans , Impetigo/diagnosis , Impetigo/pathology , Skin Diseases, Vesiculobullous/diagnosis , Skin Diseases, Vesiculobullous/pathology , Diagnosis, Differential
10.
Dermatol Online J ; 29(1)2023 Feb 15.
Article in English | MEDLINE | ID: mdl-37040917

ABSTRACT

Bullous impetigo is a variant of epidermal infection by Staphylococcus aureus, representing 30% of impetigo cases. Its clinical appearance may mimic certain autoimmune blistering dermatoses and other cutaneous infections, sometimes necessitating careful evaluation. Herein we present a patient with bullous impetigo in a striking and characteristic appearance and briefly overview the approach to diagnosis, treatment, and prevention.


Subject(s)
Autoimmune Diseases , Impetigo , Skin Diseases , Staphylococcal Infections , Male , Humans , Impetigo/diagnosis , Blister , Abdomen
13.
J Coll Physicians Surg Pak ; 32(3): 380-382, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35148595

ABSTRACT

Bullous scabies (BS) is a rare and atypical presentation of scabies, usually affecting elderly males during the seventh decade of life. BS is characterised by intense pruritic eruptions, nocturnal itch, and characteristic blisters with or without burrows in scabies-prone areas. The scabies lesions might predispose patients to bacterial super-infections, resulting in bullae formation similar to bullous impetigo. The diagnosis of BS is often puzzling and delayed. Few cases of BS have been reported among children globally. We, herein, report a case of BS in an eight-year boy from Pakistan, treated successfully with 5% topical permethrin and 2% mupirocin. Complete healing was noted within four weeks with no recurrence at two months follow-up. Key Words: Scabies, Bullous, Child, Diagnosis, Treatment.


Subject(s)
Impetigo , Scabies , Aged , Blister , Child , Family , Humans , Impetigo/diagnosis , Impetigo/drug therapy , Male , Pruritus , Scabies/diagnosis , Scabies/drug therapy
14.
Trials ; 23(1): 108, 2022 Feb 02.
Article in English | MEDLINE | ID: mdl-35109906

ABSTRACT

BACKGROUND: Impetigo is a common and contagious bacterial skin infection, affecting children worldwide, but it is particularly prevalent in socioeconomically disadvantaged communities. In New Zealand, widespread prescribing of the topical antibiotic fusidic acid had led to an increase in antimicrobial resistance of Staphylococcus aureus. Alternative treatments are urgently being sought, and as impetigo is a superficial infection, it has been suggested that topical antiseptics such as hydrogen peroxide or simple wound care alone may treat impetigo while avoiding the risk of increased antimicrobial resistance. METHODS: This protocol for a non-inferiority, single-blind randomised controlled trial compares topical fusidic acid with topical hydrogen peroxide and with simple wound care in the treatment of childhood impetigo. Participants are randomised to one of the three treatments for 5 days. The primary outcome is clinical improvement assessed through paired photographs analysed by graders blinded to treatment arm. The trial is based in school health clinics in an urban centre in New Zealand. Comparison of antimicrobial resistance patterns pre- and post-treatment is also performed. DISCUSSION: Special note is made of the need to involve the communities most affected by impetigo in the design and implementation of the clinical trial to recruit the children most in need of safe and effective treatments. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR) 12616000356460 . Registered on March 10, 2016  Protocol amendment number: 05 EB and AL contributed equally as senior authors.


Subject(s)
Anti-Infective Agents, Local , Impetigo , Anti-Bacterial Agents/adverse effects , Anti-Infective Agents, Local/adverse effects , Australia , Child , Humans , Impetigo/diagnosis , Impetigo/drug therapy , New Zealand , Schools , Single-Blind Method
15.
Pediatr Dermatol ; 39(2): 320-321, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35014095

ABSTRACT

Contact dermatitis usually presents as erythematous macules, papules, and vesicles. Sometimes, unusual clinical presentations of contact dermatitis are reported, including pustular, lymphomatoid, lichenoid, and pigmented variants. We describe the first patient with bullous irritant contact dermatitis caused by perfume, mimicking impetigo lesions. We report this case to raise awareness concerning the possibility of serious cutaneous reactions, such as bullous impetigo-like irritant contact dermatitis due to perfumes which are ubiquitous, especially after direct contact with the solution. Perfume ingredients, such as fragrance, solvents, and preservatives all may cause or contribute to irritant contact dermatitis.


Subject(s)
Dermatitis, Allergic Contact , Dermatitis, Contact , Dermatitis, Irritant , Impetigo , Perfume , Soft Tissue Injuries , Dermatitis, Allergic Contact/etiology , Dermatitis, Contact/etiology , Dermatitis, Irritant/diagnosis , Dermatitis, Irritant/drug therapy , Dermatitis, Irritant/etiology , Humans , Impetigo/diagnosis , Impetigo/drug therapy , Irritants
16.
Pan Afr Med J ; 43: 104, 2022.
Article in English | MEDLINE | ID: mdl-36699980

ABSTRACT

Pustular psoriasis of pregnancy (PPP) also known as impetigo herpetiformis is a well-described dermatosis of pregnancy characterized by the fatal progression of disease for both the mother and the foetus if left untreated. A 28-year-old G2P1L1 pregnant mother at 28 weeks of gestation, came to outpatient department (OPD) with complaints of scaly skin lesions all over her body along with fever, nausea and generalised weakness. On examination, there were erythematous scaly patches in the trunk, back, hands and legs accompanied by formation of pustules in the periphery of the lesions. Histopathological examination was consistent with pustular psoriasis. Patient was managed with prednisolone (40 mg/day which was later tapered). Serial antenatal visits and ultrasounds were done to monitor the health of the mother and foetal growth. Under the support of obstetrician, patient delivered a healthy female baby through caesarean section under general anaesthesia. Her lesions persisted in the postpartum period, which later started reducing gradually.


Subject(s)
Dermatitis Herpetiformis , Impetigo , Psoriasis , Skin Diseases, Vesiculobullous , Humans , Pregnancy , Female , Adult , Impetigo/complications , Impetigo/diagnosis , Impetigo/pathology , Dermatitis Herpetiformis/diagnosis , Cesarean Section , Psoriasis/diagnosis , Psoriasis/drug therapy , Skin/pathology , Skin Diseases, Vesiculobullous/pathology
18.
J Chemother ; 34(5): 279-285, 2022 Sep.
Article in English | MEDLINE | ID: mdl-34405763

ABSTRACT

Bacterial impetigo is one of the most common skin infection in childhood. Uncertainty exists about its management. This article offers practical suggestions, given the existing evidence and experts' opinions, for correctly managing pediatric impetigo in both hospital and ambulatory settings. Italian physicians with an expertise on pediatric impetigo appointed a working group. A preliminary literature search using Pubmed/MEDLINE and Cochrane Library databases has been performed. The most common controversial issues about pediatric impetigo have been identified and then discussed from multidisciplinary perspectives, according to the 'structured controversy' methodology, a technique discovered and designed to get engaged in a controversy and then guide participants to seek consensus. The expert panels identified 10 main controversies about pediatric impetigo. All of them have been discussed from dermatological, pediatric, pharmacological and microbiological points of view reaching consensus. Each controversy has been revised thus giving practical issues for an easy use in clinical practice. Based on clinical experts' opinion, local epidemiology and literature review this article offers practical suggestions for the management of pediatric impetigo trying to reduce uncertainty in this setting of care.


Subject(s)
Impetigo , Quinolones , Aminopyridines/pharmacology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Cellulitis/drug therapy , Child , Humans , Impetigo/diagnosis , Impetigo/drug therapy , Quinolones/pharmacology
20.
Fam Pract ; 39(1): 150-158, 2022 01 19.
Article in English | MEDLINE | ID: mdl-34184743

ABSTRACT

BACKGROUND: Impetigo is a common superficial skin infection that affects people worldwide and is usually treated with antibiotics; therefore, its management has implications for global antibiotic stewardship. OBJECTIVE: This systematic review and narrative synthesis compares and contrasts international impetigo management guidelines. METHODS: Guidelines for treatment of impetigo that were produced by a national authority; available to primary care physicians; and published since 2008 were included. Following a comprehensive search strategy, data extraction from eligible studies was performed independently in duplicate. Details of antiseptic and antibiotic treatment; methicillin-resistant Staphylococcus aureus treatment; and conservative management and preventative measures were tabulated and analysed descriptively. RESULTS: Fifty-one guidelines were included from 42 different countries. All guidelines recommended systemic antibiotics, 78% of these only for widespread lesions or failure of topical antibiotic treatment. The first-line systemic antibiotic treatment was restricted to narrow-spectrum options in 21 (41%) whilst 7 (14%) recommended only broad-spectrum antibiotics first-line. Thirty-four (67%) guidelines included recommendations for topical antibiotic use. Twenty guidelines (39%) did not mention antiseptic treatment for impetigo. Guidelines did not always provide clear indications for different treatment options. CONCLUSIONS: Despite potentially equal efficacy to systemic antibiotics, only two-thirds of guidelines include topical antibiotic options. Many fail to include recommendations for non-antibiotic treatments such as antiseptics, preventative measures and conservative management, despite potential for antibiotic-sparing. Provision of clear definitions of disease severity and indications for treatment would enhance the ability of clinicians to adhere to recommendations. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018117770.


Subject(s)
Antimicrobial Stewardship , Impetigo , Methicillin-Resistant Staphylococcus aureus , Anti-Bacterial Agents/therapeutic use , Humans , Impetigo/diagnosis , Impetigo/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL